Ambry Genetics (Ambry), a pioneer in clinical diagnostic testing and a division of REALM IDx, and Unilabs, a top provider of diagnostic services, have partnered exclusively to improve high-quality genetic testing services for government-sponsored and biopharma companies conducting global clinical trials and research.
In places where Ambry doesn’t have a physical presence, such as Europe, Latin America, and the Middle East, Ambry will utilise Unilabs’ genomic lab services and variant interpretation skills. Additionally, Unilabs will offer genetic testing, patient cohort recruitment for clinical trials, patient identification, and stratification for individualized care.
Ambry will make its variant assessment tools available to Unilabs. It also has intentions to make its CARE ProgramTM available, even though it is only now offered in the U.S. and Japan (Comprehensive Assessment Risk and Education). The CARE Program makes use of a variety of digital health tools to find patients who are at higher risk for specific illnesses and/or who are eligible for genetic testing, educate patients, make ordering and reporting genetic tests and test results easier, and link patients to genetic counselling. The workflows of a clinic or system are integrated with this end-to-end program to support medical professionals and their patients at every stage.
“We are thrilled that our long tradition of serving pharmaceutical companies and outstanding track record in providing best-in-class diagnostics in support of research and drug development got us this exclusive partnering with Ambry Genetics”, “Together with our industry-leading clinical laboratory, radiology and digital pathology services, we provide access to a test menu of more than 4,000 genetic tests. This expertise will allow us to provide enhanced assessments to help support important drug discoveries in compliance with local legislation on patient data protection, genomic testing and clinical trials.”
Dr. Christian Rebhan, President – Scientific Business Units and Chief Medical Officer, Unilabs
Together, Unilabs and Ambry will address the lack of consistency in laboratory testing techniques and analysis, one of the major obstacles to the use of genomics in international clinical trials.
“We want to help global biopharma companies find the right patient at the right time for their trials and therapies around the world”, “Through our partnership with Unilabs, we will be able to provide biopharma companies the support they need to develop new therapies faster and more efficiently and serve physicians, patients and government programs locally.”
Tom Schoenherr, CEO of Ambry
Through its local global lab network and its other alliances, Ambry offers genetic testing services to 30 nations.